Axsome Therapeutics AXSM Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's total equity?
- Axsome Therapeutics (AXSM) reported total equity of $54.59M in Q1 2026.
- How has Axsome Therapeutics's total equity changed year-over-year?
- Axsome Therapeutics's total equity increased by 2.6% year-over-year, from $53.21M to $54.59M.
- What is the long-term trend for Axsome Therapeutics's total equity?
- Over 5 years (2020 to 2025), Axsome Therapeutics's total equity has grown at a -4.9% compound annual growth rate (CAGR), from $113.79M to $88.3M.
- What does total equity mean?
- The net value of the company belonging to shareholders after all debts are paid.
- How do you interpret total equity?
- An increase suggests growth in net assets or successful capital raises, while a decrease may signal losses or share buybacks.
- How does total equity compare across companies?
- Standard metric used to assess the financial health and solvency of a company relative to its peers.